Abstract

The results establish the efficacy of fixed-dose oral ximelagatran without coagulation monitoring compared with well-controlled warfarin for prevention of thromboembolism in patients with atrial fibrillation requiring chronic anticoagulant therapy, but the potential for hepatotoxicity requires further investigation.

Keywords

MedicineXimelagatranWarfarinAtrial fibrillationStroke (engine)Confidence intervalClinical endpointInternal medicineCardiologyEmbolismRelative riskRate ratioAnesthesiaRandomized controlled trialDabigatran

Affiliated Institutions

Related Publications

Research Agenda for Frailty in Older Adults: Toward a Better Understanding of Physiology and Etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults

Jeremy Walston , Marianne Nygaard , Luigi Ferrucci +6 more

Evolving definitions of frailty, and improved understanding of molecular and physiological declines in multiple systems that may increase vulnerability in frail, older adults ha...

2006 Journal of the American Geriatrics So... 1589 citations

Publication Info

Year
2005
Type
article
Volume
293
Issue
6
Pages
690-690
Citations
660
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

660
OpenAlex

Cite This

Gregory W. Albers, Hans‐Christoph Diener, Lars Frison et al. (2005). Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. JAMA , 293 (6) , 690-690. https://doi.org/10.1001/jama.293.6.690

Identifiers

DOI
10.1001/jama.293.6.690